Search results
Results from the WOW.Com Content Network
Epstein–Barr virus positive diffuse large B-cell lymphoma, not otherwise specified (EBV+ DLBCL, NOS) is a form of diffuse large B-cell lymphomas (DLBCL) accounting for around 10-15% of DLBCL cases. DLBCL are lymphomas in which B-cell lymphocytes proliferate excessively, invade multiple tissues, and often causes life-threatening tissue damage.
As of 2007, ABVD is widely used as the initial chemotherapy treatment for newly diagnosed Hodgkin lymphoma. [citation needed] It has been the most effective and least toxic chemotherapy regimen available for treating early-stage Hodgkin Lymphoma. [1]
Stanford V (usually spoken as Stanford Five), is a chemotherapy regimen (with accompanying Radiation therapy) intended as a first-line treatment for Hodgkin lymphoma.The regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens ...
FCM, or FMC in the context of chemotherapy is an acronym for a chemotherapy regimen that is used in the treatment of indolent B cell non-Hodgkin's lymphomas.In combination with Rituximab, this regimen is called R-FCM or R-FMC, or FCM-R, FMC-R.
BEACOPP is a chemotherapy regimen for treatment of Hodgkin lymphoma developed by the German Hodgkin Study Group [1] used for patients in Stages > II or early (IA or IB) with unfavorable risk factors. [2]
Loncastuximab tesirine, sold under the brand name Zynlonta, is a monoclonal antibody conjugate medication used to treat large B-cell lymphoma and high-grade B-cell lymphoma. [ 1 ] [ 2 ] It is an antibody-drug conjugate (ADC) composed of a humanized antibody targeting the protein CD19 .
However, research shows that certain chemotherapy drugs can, under specific conditions, boost the immune response against tumors and enhance the effectiveness of immunotherapy. [ 6 ] Chemotherapy can boost tumor immunity in two main ways: (a) by killing cancer cells through immunogenic cell death , and (b) by affecting both cancerous and normal ...
In these conditions HDC can act as a salvage therapy that proves beneficial, for patients potentially leading to long lasting remission. [5] Schmitz and colleagues important study showed that high dose chemotherapy followed by stem cell transplantation (ASCT) could lead to better outcomes in individuals with recurrent Hodgkins lymphoma. [6]